Please select the option that best describes you:
Topics:
Gynecologic Cancers • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University
Is it safe and/or necessary to combine osimertinib and carboplatin/paclixel for a patient with stage IV EGFR mutated NSCLC and advanced ovarian carcinoma?
Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however if the NSCLC is not responding but the ovarian cancer is, combining chemotherapy with TKI is not addressed in the guidelines.
Answer from: Medical Oncologist at Academic Institution
This is a tough situation and a lot depends on the status and urgency of the ovarian cancer and whether surgery is planned for it. I would not combine the chemotherapy and osimertinib simultaneously for sure. There are several studies that show the combination of chemo and TKI is not as good as TKI ...
Sign in or Register to read more